Bailard’s Avadel Pharmaceuticals AVDL Stock Holding History

Bailard’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-293,000	Closed	-$2.37M	–	556
2020 Q2	$2.37M	Buy	293,000 +203,000	+226%	+$1.79M	0.13%	129
2020 Q1	$715K	Buy	+90,000	New	+$691K	0.05%	197
2018 Q1	–	Sell	-141,000	Closed	-$1.16M	–	477
2017 Q4	$1.16M	Hold	141,000	–	–	0.07%	224
2017 Q3	$1.48M	Hold	141,000	–	–	0.11%	145
2017 Q2	$1.55M	Hold	141,000	–	–	0.13%	150
2017 Q1	$1.36M	Buy	+141,000	New	+$1.41M	0.11%	155
2016 Q4	–	Sell	-120,700	Closed	-$1.5M	–	305
2016 Q3	$1.5M	Buy	120,700 +17,700	+17%	+$231K	0.14%	138
2016 Q2	$1.11M	Buy	+103,000	New	+$1.1M	0.13%	151
2015 Q3	–	Sell	-155,000	Closed	-$3.28M	–	248
2015 Q2	$3.28M	Sell	155,000 -90,000	-37%	-$1.61M	0.51%	31
2015 Q1	$4.41M	Buy	245,000 +110,000	+81%	+$1.72M	0.61%	21
2014 Q4	$2.31M	Sell	135,000 -100,000	-43%	-$1.43M	0.33%	51
2014 Q3	$3.36M	Hold	235,000	–	–	0.52%	31
2014 Q2	$3.52M	Buy	235,000 +175,000	+292%	+$2.11M	0.54%	29
2014 Q1	$804K	Buy	+60,000	New	+$643K	0.13%	99

Other funds holding AVDL

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GJL

Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Bailard's AVDL Position: Q3 2020 in Review

Bailard sold out of Avadel Pharmaceuticals (AVDL) in Q3 2020, closing a stake of 293,000 shares — an estimated $2.37M sold.

Bailard first reported a position in AVDL in Q1 2014 and held it in 14 quarters. The position peaked at $4.41M in Q1 2015. 79 funds tracked by Wall St. Rank hold AVDL as of Q3 2020.

Bailard reported no remaining Avadel Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Bailard sold 293,000 Avadel Pharmaceuticals shares in Q3 2020, an estimated $2.37M.
Bailard first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 14 quarters.
Bailard's Avadel Pharmaceuticals position peaked at $4.41M in Q1 2015.
79 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2020.

Based on Bailard's 13F filing for Q3 2020, filed 10 Nov 2020.